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The advent of soft ionization techniques such as electrospray 
ionization (ESI) and matrix assisted laser desorption ionization 
(MALDI) in the late 1980s, for which the inventers were jointly awarded 
the 2002 Nobel prize in Chemistry, rendered liquid chromatography-
tandem mass spectrometry (LC-MS/MS) an indispensable tool for 
analyses of small and macro-molecules in biological fluids. Recent 
improvements in sensitivity and affordability have encouraged the 
adoption of this technology for routine applications in the clinical 
laboratory. However, the major driving force for the rapid expansion of 
this technology in the last decade remains the advantages it offered in 
comparison with other technologies, such as gas chromatography-mass 
spectrometry (GC-MS) and immunoassays. Unlike GC-MS, LC-MS/
MS does not require laborious sample preparation procedures, which 
often involve tedious derivatization, or lengthy chromatographic run 
times. In fact, it is now common to see published LC-MS/MS methods 
that require only protein precipitation, solid-phase extraction or liquid-
liquid extraction with chromatographic run times not exceeding 5 
minutes. In addition, LC-MS/MS widened the spectrum of analytes that 
can be measured by MS because it is not limited by molecular mass or 
polarity of the target analytes compared to GC-MS [1]. As a result, LC-
MS/MS has found numerous applications in particularly challenging 
areas like endocrinology (steroids), therapeutic drug monitoring 
(immunosuppressants), inborn errors of metabolism (organic acids and 
acylcarnitines), clinical and forensic toxicology (drugs of abuse testing), 
and nutrition assessment (vitamins). Also, with the advancement in 
MALDI-TOF and orbitrap technologies, these applications have been 
expanded to microbiology, metabolomics, proteomics and lipidomics 
[2,3]. On the other hand, in comparison with immunoassays, LC-MS/
MS offers much lower throughput but requires lower reagent cost per 
test with a much higher specificity for most applications, which is why 
this technique is often considered the “gold standard”. For instance, the 
American Endocrine Society issued a statement in 2007 recommending 
the use of LC-MS/MS over immunoassays for the determination of 
steroid hormones [4]. 
Major areas for improvement of this technology remain, including 
throughput, complexity, standardization, instrument cost, field 
service, and interfacing with laboratory information systems (LIS). 
Manufacturers are gearing up the effort to increase the throughput of LC-
MS/MS with some manufacturers introducing multiplexing capabilities 
that allow connection of up to four parallel LC systems synchronized 
to a single MS analyzer, which allows multiple samples to be analyzed 
simultaneously. Others have partnered with the automation industry to 
work on fully automate solutions from sample preparation to analysis. 
Nevertheless, the number of LC-MS/MS instruments currently in use in 
clinical laboratories is still limited when compared with other diagnostic 
analyzers for several reasons. First, the Achilles’ heel of LC-MS/MS is its 
complexity and the need for highly skilled laboratory staff to assist with 
method development and thorough validation as well as maintaining 
the instruments. While some manufacturers are now assisting with the 
process and are offering “kits” that include columns, calibrators and 
controls, most tests offered on LC-MS/MS remain “home brew” assays 
and standardization remains a critical issue to address. To confound 
the issue, the lack of national guidelines and general agreement on what 
constitutes acceptable validation criteria for LC-MS/MS assays, renders 
these assays susceptible to failure, especially if the common issue of 
matrix effects is not thoroughly evaluated and addressed. Another 
major hurdle is the large initial cost required to purchase the instrument 
($200,000 to $400,000), which can be a deterring factor for smaller 
laboratories. The lack of appropriate field service support that meets the 
needs of a clinical lab is another limitation to the wide adoption of LC-
MS/MS. Finally, there has been little to no effort interfacing LC-MS/MS 
with LIS, which is crucial in eliminating specimen mis-identification 
and post-analytical transcription errors, especially in high volume 
laboratories. 
LC-MS/MS offers great potential for the diagnostic laboratory in 
spite of all of the associated challenges. In the US, the Clinical and 
Laboratory Standards Institute (CLSI) has recognized the need for a 
uniform set of guidelines for validation of LC-MS/MS methods, and 
has gathered the experts in the field to create one. Its release is expected 
imminent and represents a significant step forward in ensuring 
high quality methods to be used for patient care. Moving forward, 
communication with manufacturers is also crucial to making sure 
the needs of the clinical laboratory are met in terms of field service, 
affordability, automation, and LIS interfacing.
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